

# Noel Chan Mbbs

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2151108/noel-chan-mbbs-publications-by-year.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

59  
papers

929  
citations

19  
h-index

29  
g-index

70  
ext. papers

1,247  
ext. citations

6.4  
avg, IF

5.29  
L-index

#	Paper	IF	Citations
59	Can a Single Measurement of Apixaban Levels Identify Patients at Risk of Overexposure? A Prospective Cohort Study.. <i>TH Open</i> , <b>2022</b> , 6, e10-e17	2.7	2
58	Carbamazepine, phenytoin, and oral anticoagulants: Drug-drug interaction and clinical events in a retrospective cohort.. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2022</b> , 6, e12650	5.1	1
57	Management of a left atrial appendage thrombus due to atrial fibrillation complicating Quebec platelet disorder.. <i>Canadian Journal of Cardiology</i> , <b>2022</b> ,	3.8	
56	No apparent association between mRNA COVID-19 vaccination and venous thromboembolism.. <i>Blood Reviews</i> , <b>2022</b> , 100970	11.1	3
55	In pregnant women with suspected VTE and low/intermediate or unlikely pretest probability, D-dimer rules out VTE at 3 mo. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, JC130	8	
54	Prevention and Management of Urgent/Emergent Limb Ischemia. <i>Current Cardiology Reports</i> , <b>2021</b> , 23, 41	4.2	1
53	Medical Therapy Following Urgent/Emergent Revascularization in Peripheral Artery Disease Patients (Canadian Acute Limb Ischemia Registry [CANALISE I]).. <i>CJC Open</i> , <b>2021</b> , 3, 1325-1332	2	0
52	A National Canadian Survey of Antithrombotic Therapy After Urgent and Emergent Limb Revascularization. <i>Canadian Journal of Cardiology</i> , <b>2021</b> , 37, 504-507	3.8	4
51	Plasma Rivaroxaban Level to Identify Patients at Risk of Drug Overexposure: Is a Single Measurement of Drug Level Reliable?. <i>TH Open</i> , <b>2021</b> , 5, e84-e88	2.7	1
50	Advances in the Management of Acute Venous Thromboembolism and New Therapeutic Agents. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2021</b> , 42, 218-232	3.9	
49	Hypercoagulability and thrombosis in COVID-19: a modifiable cause for mortality?. <i>European Heart Journal</i> , <b>2021</b> , 42, 3143-3145	9.5	4
48	Strategies for the prevention and treatment of bleeding in patients treated with dabigatran: an update. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2021</b> , 17, 1091-1102	5.5	0
47	Refining Risk Prediction for Recurrent Venous Thromboembolism: Can We Do Better?. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 725-727	7	1
46	Recent advances in understanding, diagnosing and treating venous thrombosis. <i>F1000Research</i> , <b>2020</b> , 9,	3.6	2
45	Apixaban for Stroke Prevention in Atrial Fibrillation: Why are Event Rates Higher in Clinical Practice than in Randomized Trials?-A Systematic Review. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 1323-1329	7	11
44	Direct oral anticoagulants: evidence and unresolved issues. <i>Lancet, The</i> , <b>2020</b> , 396, 1767-1776	40	32
43	Plasma Apixaban Levels in Patients Treated Off Label With the Lower Dose. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 2906-2907	15.1	4

42	Rivaroxaban for the prevention of major adverse cardiovascular events in patients with coronary or peripheral artery disease. <i>Future Cardiology</i> , <b>2020</b> , 16, 597-611	1.3	
41	COVID-19 coagulopathy, thrombosis, and bleeding. <i>Blood</i> , <b>2020</b> , 136, 381-383	2.2	48
40	Prevention of Venous Thromboembolism in 2020 and Beyond. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	26
39	Peripheral Oxygen Saturation in Older Persons Wearing Nonmedical Face Masks in Community Settings. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 324, 2323-2324	27.4	31
38	Novel antithrombotic strategies for treatment of venous thromboembolism. <i>Blood</i> , <b>2020</b> , 135, 351-359	2.2	25
37	Thromboembolism in Older Adults. <i>Frontiers in Medicine</i> , <b>2020</b> , 7, 470016	4.9	1
36	Reduction in Mortality following Elective Major Hip and Knee Surgery: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , <b>2019</b> , 119, 668-674	7	15
35	Antithrombotic Agents. <i>Circulation Research</i> , <b>2019</b> , 124, 426-436	15.7	43
34	Response by Chan and Weitz to Letter Regarding Article, "Antithrombotic Agents: New Directions in Antithrombotic Therapy". <i>Circulation Research</i> , <b>2019</b> , 124, e119	15.7	1
33	Impact of Platelet Endothelial Aggregation Receptor-1 Genotypes on Platelet Reactivity and Early Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention and Treated With Aspirin and Clopidogrel. <i>Circulation: Cardiovascular Interventions</i> , <b>2019</b> , 12, e007019	6	11
32	Utility of a Nurse-Led Pathway for Patients with Acute Venous Thromboembolism Discharged on Rivaroxaban: A Prospective Cohort Study. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2019</b> , 45, 187-195	5.3	3
31	Antiplatelet Drugs in the Management of Venous Thromboembolism, Cardioembolism, Ventricular Assist Devices, and Pregnancy Complications <b>2019</b> , 1067-1077		
30	How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism. <i>Blood</i> , <b>2019</b> , 133, 2269-2278	2.2	8
29	MAA868 locks factor XIa in a zymogen-like state. <i>Blood</i> , <b>2019</b> , 133, 1393-1394	2.2	5
28	Fifty years of research on antithrombotic therapy: Achievements and disappointments. <i>European Journal of Internal Medicine</i> , <b>2019</b> , 70, 1-7	3.9	9
27	Long-Term Management of Venous Thromboembolism: Lessons from EINSTEIN CHOICE and Other Extension Trials. <i>Thrombosis and Haemostasis</i> , <b>2019</b> , 119, 689-694	7	9
26	Rivaroxaban for prevention and treatment of venous thromboembolism. <i>Future Cardiology</i> , <b>2019</b> , 15, 63-77	1.3	5
25	The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. <i>Thrombosis and Haemostasis</i> , <b>2019</b> , 119, 14-38	7	19

24	Advances in Antithrombotic Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2019</b> , 39, 7-12	9.4	24
23	Incidence and risk factors for acute kidney injury in patients with excessive anticoagulation on warfarin: a retrospective study. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2018</b> , 45, 557-561	5.1	8
22	Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants?. <i>American Heart Journal</i> , <b>2018</b> , 199, 59-67	4.9	15
21	In Vitro Reversal of the Anti-Aggregant Effect of Ticagrelor Using Untreated Platelets. <i>Thrombosis and Haemostasis</i> , <b>2018</b> , 118, 1895-1901	7	8
20	Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2018</b> , 2, 684-688	5.1	42
19	Antiplatelet therapy in the management of atherothrombosis: recent clinical advances. <i>Blood Advances</i> , <b>2018</b> , 2, 1806	7.8	1
18	In high-risk patients with arthritis and previous upper GI bleeding, celecoxib vs naproxen reduced recurrent bleeding. <i>Annals of Internal Medicine</i> , <b>2017</b> , 167, JC17	8	
17	Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial. <i>TH Open</i> , <b>2017</b> , 1, e139-e145	2.7	15
16	Platelet function testing: does a randomized controlled trial settle the debate?. <i>Journal of NeuroInterventional Surgery</i> , <b>2016</b> , 8, 768-9	7.8	3
15	Antiplatelet therapy: Net benefit of ticagrelor in patients with chronic kidney disease. <i>Nature Reviews Nephrology</i> , <b>2016</b> , 12, 10-1	14.9	0
14	Laboratory measurement of the direct oral anticoagulants. <i>British Journal of Haematology</i> , <b>2016</b> , 172, 315-36	4.5	65
13	Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants. <i>Circulation Research</i> , <b>2016</b> , 118, 1409-24	15.7	76
12	A systematic review of contemporary trials of anticoagulants in orthopaedic thromboprophylaxis: suggestions for a radical reappraisal. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2015</b> , 40, 231-9	5.1	22
11	Evaluating coagulation tests in patients with atrial fibrillation using direct oral anticoagulants. <i>Expert Review of Cardiovascular Therapy</i> , <b>2015</b> , 13, 1213-23	2.5	1
10	Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valve-Induced Thrombin Generation. <i>Journal of the American Heart Association</i> , <b>2015</b> , 4, e002322	6	60
9	Real-world variability in dabigatran levels in patients with atrial fibrillation: reply. <i>Journal of Thrombosis and Haemostasis</i> , <b>2015</b> , 13, 1168-9	15.4	5
8	Lack of consistency in the relationship between asymptomatic DVT detected by venography and symptomatic VTE in thromboprophylaxis trials. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 114, 1049-57	7	21
7	Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. <i>Vascular Health and Risk Management</i> , <b>2015</b> , 11, 343-51	4.4	58

6	Timing the First Postoperative Dose of Anticoagulants: Lessons Learned From Clinical Trials. <i>Chest</i> , <b>2015</b> , 148, 587-595	5.3	11
5	Real-world variability in dabigatran levels in patients with atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , <b>2015</b> , 13, 353-9	15.4	50
4	Role of phenotypic and genetic testing in managing clopidogrel therapy. <i>Blood</i> , <b>2014</b> , 124, 689-99	2.2	26
3	Mandatory contrast-enhanced venography to detect deep-vein thrombosis (DVT) in studies of DVT prophylaxis: upsides and downsides. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 111, 10-3	7	8
2	Betrixaban (PRT054021): pharmacology, dose selection and clinical studies. <i>Future Cardiology</i> , <b>2014</b> , 10, 43-52	1.3	27
1	New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 111, 798-807	7	38